High expression of GPR160 in prostate cancer is unrelated to CARTp-mediated signaling pathways
Acta Pharm Sin B
.
2024 Mar;14(3):1467-1471.
doi: 10.1016/j.apsb.2023.11.025.
Epub 2023 Nov 24.
Authors
Chenyu Ye
1
,
Qingtong Zhou
1
2
,
Shi Lin
2
,
Wensheng Yang
3
,
Xiaoqing Cai
4
5
,
Yiting Mai
2
,
Yanyan Chen
2
,
Dehua Yang
2
4
5
6
,
Ming-Wei Wang
1
2
7
8
Affiliations
1
Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
2
Research Center for Deepsea Bioresources, Sanya 572025, China.
3
Department of Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China.
4
State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
5
The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
6
University of Chinese Academy of Sciences, Beijing 100049, China.
7
Department of Chemistry, School of Science, the University of Tokyo, Tokyo 113-0033, Japan.
8
School of Pharmacy, Hainan Medical University, Haikou 571199, China.
PMID:
38487007
PMCID:
PMC10935005
DOI:
10.1016/j.apsb.2023.11.025
No abstract available
Keywords:
CARTp; GPR160; Prostate cancer; Signaling pathway.